Volume 2.33 | Aug 22

Pulmonary Cell News 2.33 August 22, 2013
Pulmonary Cell News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Pulmonary Cell News on Twitter
 
TOP STORY
Long-Term IL-33-Producing Epithelial Progenitor Cells in Chronic Obstructive Lung Disease
Previous analysis of parainfluenza virus infection in mice revealed an unexpected role for innate immune cells in IL-13-dependent chronic lung disease, but the upstream driver for the immune axis in this model and in humans with similar disease was undefined. In this study, researchers demonstrated that lung levels of IL-33 are selectively increased in postviral mice with chronic obstructive lung disease and in humans with very severe chronic obstructive pulmonary disease. [J Clin Invest] Abstract | Press Release
[Free Webinar] A Guide To Successful Flow Cytometry Analysis of ALDHbr Cells - Watch Now.
 
PUBLICATIONS (Ranked by impact factor of the journal)
Relative Respiratory Syncytial Virus Cytopathogenesis in Upper and Lower Respiratory Tract Epithelium
Despite the ubiquity of upper respiratory tract (URT) infection, little is known about the relative cytopathogenesis of respiratory syncytial virus (RSV) infection in infant URT and lower respiratory tract. Researchers compared RSV cytopathogenesis in nasal- and bronchial-derived epithelium from the same individuals using novel models derived from well-differentiated primary pediatric nasal and bronchial epithelial cells. [Am J Respir Crit Care Med] Abstract

Loss of Tumor Suppressor PTEN Induces Leptin Mediated Leptin Gene Expression: A Feed-Forward Loop Operating in the Lung
Using conditional deletion of tumor suppressor gene Pten (Phosphatase and tensin homologue) in the lung epithelium in vivo in transgenic mice and human PTEN-null lung epithelial cells, researchers identified leptin driven feed-forward signaling loop. [J Biol Chem] Abstract

Histamine Stimulates Hydrogen Peroxide Production by Bronchial Epithelial Cells via Histamine H1 Receptor and Duox
Researchers found that air-liquid interface cultures of primary human bronchial epithelial cells and an immortalized bronchial epithelial cell model produce hydrogen peroxide in response to histamine. [Am J Respir Cell Mol Biol] Abstract

Effects of Water Soluble PM2.5 Extracts Exposure on Human Lung Epithelial Cells (A549): A Proteomic Study
Researchers aimed to provide new insights into the cytotoxicity of particulate matter (PM)2.5 on human lung epithelial cells (A549) at the proteomic level. Two-dimensional difference gel electrophoresis revealed a total of 27 protein spots, whose abundance were significantly altered in A549 cells exposed to water-soluble PM2.5 extracts. [J Appl Toxicol] Abstract

LUNG CANCER

β-Escin Inhibits NNK-Induction of Lung Adenocarcinoma and ALDH1A1 and RhoA/Rock Expression in A/J Mice and Growth of H460 Human Lung Cancer Cells
β-Escin, a triterpene saponin isolated from horse chestnut seeds, was tested for inhibition of lung adenoma and adenocarcinoma induced by the tobacco carcinogen 4-(methyl-nitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in female A/J mice; and its possible mode of action was evaluated using the H460 human lung cancer cell line. [Cancer Prev Res (Phila)] Abstract

Sodium Metavanadate Exhibits Carcinogenic Tendencies In Vitro in Immortalized Human Bronchial Epithelial Cells
Researchers investigated the carcinogenicity of NaVO3 in the human immortalized bronchial epithelial cell line, Beas-2B. Cells were treated with 10 μM NaVO3 for 5 weeks, with or without recovery time, followed by gene expression microarray analysis. In a separate experiment, cells were exposed to 1-10 μM NaVO3 for 4 weeks and then grown in soft agar to test for anchorage-independent growth. [Metallomics] Abstract

The Molecular Mechanism Underlying Anti-Proliferative Effect of SOCS-1 in Non-Small Cell Lung Cancer Cells
The authors investigated the therapeutic potential of gene delivery using suppressor of cytokine signaling 1 (SOCS-1), an endogenous inhibitor of intracellular signaling pathways, for the treatment of lung cancer. To examine the anti-tumor effect of SOCS-1 overexpression on non-small cell lung cancer (NSCLC) cells, NSCLC cells were infected with adenovirus-expressing SOCS-1 vector. [Cancer Sci] Abstract

Crizotinib Overcomes Hepatocyte Growth Factor-Mediated Resistance to Gefitinib in EGFR-Mutant Non-Small-Cell Lung Cancer Cells
Scientists tested whether crizotinib, a MET kinase inhibitor, can overcome two different hepatocyte growth factor (HGF)-triggered mechanisms of resistance to gefitinib in human epidermal growth factor receptor (EFGR) mutant lung cancer cell lines HCC827 and PC-9. Compared with the monotherapy, the combined treatment of crizotinib and gefitinib induced apoptosis and significantly inhibited the growth of cells in the presence of HGF by blocking the MET/PI3K/Akt pathway. [Anticancer Drugs] Abstract

The Calcineurin-NFAT-Angiopoietin-2 Signaling Axis in Lung Endothelium Is Critical for the Establishment of Lung Metastases
Researchers demonstrated that the calcineurin and nuclear factor of activated T cells (NFAT) pathway is activated specifically in lung endothelium prior to the detection of tumor cells that preferentially metastasize to the lung. Upregulation of the calcineurin pathway via deletion of its endogenous inhibitor Dscr1 leads to a significant increase in lung metastases due to increased expression of a newly identified NFAT target, Angiopoietin-2. [Cell Reports] Abstract | Graphical Abstract | Press Release

Model the Human Respiratory Epithelium with PneumaCult™-ALI. Click to View Data.
 
REVIEWS
Role of the Aryl Hydrocarbon Receptor (AhR) in Lung Inflammation
This review updates the basic immunobiology of the AhR signaling pathway with regards to inflammatory lung diseases such as asthma, chronic obstructive pulmonary disease, and silicosis following data in rodent models and humans. The authors address the therapeutic potential of targeting the AhR in regulating inflammation during acute and chronic respiratory diseases. [Semin Immunopathol] Abstract

Visit our reviews page to see a complete list of reviews in the pulmonary cell research field.
 
INDUSTRY NEWS
Final Patient Completes Prosonix’ Phase II Clinical Study with PSX1002 in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Prosonix has completed all patient dosing sessions and follow-up procedures in its Phase II clinical study with PSX1002. PSX1002 is a novel, drug-only suspension formulation of the long-acting muscarinic antagonist, glycopyrronium bromide, which is in development as a potential ‘best-in-class’ orally inhaled monotherapy for COPD. [Prosonix, Ltd] Press Release

AIT Ltd. and Clalit Health Services Expand Strategic Alliance and Plan Phase II Clinical Trial for Respiratory Diseases
Israeli biomed company AIT Ltd. (Advanced Inhalation Therapies) announced that their successful collaboration with Clalit Health Services has expanded to include Schneider Children’s Medical Center of Israel as an additional clinical study site. Under this agreement, AIT will lead clinical development strategy in cooperation with Schneider’s renowned opinion leaders in the field of respiratory care. [PR Newswire Association LLC] Press Release

LungCAN Celebrates Lung Cancer Screening Breakthrough
Lung Cancer Action Network (LungCAN) members unanimously endorse lung cancer screening recommendations released in draft form recently by the U.S. Preventive Services Task Force. The Task Force recommends people between ages 55 and 79 with a minimum smoking history of 30 pack years get an annual low-dose CT scan. [Lung Cancer Action Network] Press Release

From our sponsor: Free human hematopoietic progenitors wallchart. Request a copy.
 
POLICY NEWS
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
 
EVENTS
NEW Current Controversies in the Multi-Disciplinary Management of Locally Advanced Non Small Cell Lung Cancer
December 12-13, 2013
St. Louis, United States

Visit our events page to see a complete list of events in the pulmonary cell community.
 
JOB OPPORTUNITIES
NEW PhD (Early Stage Researcher) Position – Investigation of Mucus as a Barrier for Pulmonary Drug Delivery (Helmholtz Institute for Pharmaceutical Research Saarland)

Research Technologist – Human Pluripotent Stem Cell Products (STEMCELL Technologies Inc.)

Postdoctoral Associate – Lung Cancer (Yale Cancer Center)

Professor of Immunology Centre for Infection and Immunity (Queen’s University Belfast)

Postdoctoral Research Fellow – Cancer Genomics (Fred Hutchinson Cancer Research Center)

PhD Position – Interaction of Nanoparticles with the Pulmonary Barrier (Helmholtz Institute for Pharmaceutical Research Saarland)

Postdoctoral Research Scientist – Asthma (Columbia University)

Postdoctoral Fellow – ERK3 Kinase Signaling in Cancer Progression and Metastasis (Wright State University)

Director of Cell Processing Facility (S L Collins Associates, Inc.)


Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
 

Learn more about Pulmonary Cell News: Archives | Events | Contact Us